J&J (NYSE: JNJ) said to offer hip case accord which may exceed $2B
- Wall St. declines as earnings take center stage
- After-Hours Movers 7/25: (CLGX) (TXN) (SGY) Higher; (MSTX) (CRME) (SANM) Lower
- The 7 Reasons Behind BGC's Apple (AAPL) Downgrade to Sell
- Marcato Capital Files 13D on Buffalo Wild Wings (BWLD) Showing New 5.1% Stake
- Gilead Sciences (GILD) Tops Q2 EPS by 6c
Johnson & Johnson (NYSE: JNJ) said to offer hip case accord which may exceed $2 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
- BMO Capital Reiterates Outperform on Johnson & Johnson (JNJ) Following 2Q Report
- Pre-open market-options summary
Create E-mail Alert Related CategoriesGeneral News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!